A new experimental cancer approach combines bacterial tumor targeting with nutrient deprivation and immune stimulation in a single engineered therapeutic. In work published in Nature Communications, researchers describe a conjugate built from L-asparaginase and flagellin linked to a system directing the treatment to calreticulin-bearing cancer cells. Using Salmonella-mediated tumor therapy models, the authors report the strategy enhanced antitumor effectiveness compared with alternatives, consistent with the conjugate’s dual role in depleting asparagine while activating innate immune pathways through flagellin. For oncology drug developers, the study highlights a platform direction: engineering multi-function agents that simultaneously alter tumor metabolism and stimulate immune engagement—potentially improving response depth in tumors that resist standard monotherapy.